Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 3, 1998, Pages 402-404

  Lycke, J N ^a   Karlsson, J E ^b   Andersen, O ^a   Rosengren, L E ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrospinal fluid; Marker of disease activity; Multiple sclerosis; Neurofilament

Indexed keywords

NEUROFILAMENT PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NERVE FIBER; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; TIME;

EID: 0031922504     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.3.402     Document Type: Article

References (15)

1. Lasek RJ. Studying the intrinsic determinants of neuronal form and function. In: Lasek RJ, Black MM, ed. Intrinsic determinants of neuronal form and function. New York: Allan R Liss, 1988.
2. Karlsson J-E, Rosengren LE, Haglid KG. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexanedione. J Neurochem 1991;57:1437-44.
3. Wang S, Lees GJ, Rosengren LE, et al. The effect of an N-methyl-D-aspartate lesion in the hippocampus on glial and neuronal marker proteins. Brain Res 1991;541: 334-41.
4. Rosengren L, Karlsson J-E, Karlsson J-O, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-8.
5. Adams CWM. The onset and progression of the lesion in multiple sclerosis. J Neurol Sci 1975;25:165-82.
6. Barnes D, Munro PMG, Youl BD, et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain 1991;114:1271-80.
7. MacFadyen DJ, Drance SM, Douglas GR, et al. The retinal nerve fiber layer, neuroretinal rim area, and visual evoked potentials in MS. Neurology 1988;38:1353-8.
8. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
9. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-7.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
12. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996;243:214-24.
13. Rieckhmann P, Martin S, Weichselbraun I, et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 1994;44: 2367-72.
14. Shaw CE, Dunbar PR, Macaulay HA, et al. Measurement of immune markers in serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol 1995;242:53-8.
15. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995;133:61-5.